EverSource Wealth Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 121.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,006 shares of the biopharmaceutical company's stock after purchasing an additional 12,061 shares during the quarter. EverSource Wealth Advisors LLC's holdings in Pfizer were worth $962,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Karp Capital Management Corp purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $27,000. Steward Financial Group LLC raised its holdings in shares of Pfizer by 315.3% during the 2nd quarter. Steward Financial Group LLC now owns 544 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 413 shares during the period. Worth Asset Management LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $29,000. Goodman Advisory Group LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $32,000. Finally, Gladius Capital Management LP raised its holdings in shares of Pfizer by 101.6% during the 2nd quarter. Gladius Capital Management LP now owns 975 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 60,528 shares during the period. 67.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. The Goldman Sachs Group upgraded Pfizer from a "neutral" rating to a "buy" rating and raised their target price for the company from $47.00 to $60.00 in a report on Tuesday, December 13th. SVB Leerink raised their target price on Pfizer from $48.00 to $49.00 and gave the company a "market perform" rating in a report on Thursday, November 3rd. Wells Fargo & Company downgraded Pfizer from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $54.00 to $50.00 in a report on Tuesday, January 17th. UBS Group downgraded Pfizer from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $55.00 to $47.00 in a report on Thursday. Finally, JPMorgan Chase & Co. set a $50.00 price objective on Pfizer in a report on Wednesday, January 18th. Eight equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $52.33.

Pfizer Stock Performance

Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the consensus estimate of $1.47 by $0.31. The company had revenue of $22.64 billion during the quarter, compared to analyst estimates of $21.04 billion. Pfizer had a return on equity of 43.95% and a net margin of 29.81%. On average, equities analysts expect that Pfizer Inc. will post 6.47 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, January 26th. This represents a $1.64 dividend on an annualized basis and a yield of 3.72%. This is a positive change from Pfizer's previous quarterly dividend of $0.40. Pfizer's payout ratio is currently 30.77%.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Articles

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market
• PCE Indicates Slowdown In Spending, Economy Weakens
• Microsoft's Comeback Is Now Underway
• Can Amazon Recover Amid Tech Stock Sell-off?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.